

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23L 1/29, 1/09, 1/30, 1/305, A61K 31/70, 31/715	A1	(11) International Publication Number: WO 97/38593 (43) International Publication Date: 23 October 1997 (23.10.97)
(21) International Application Number: PCT/US97/05316 (22) International Filing Date: 28 March 1997 (28.03.97) (30) Priority Data: 08/631,584 12 April 1996 (12.04.96) US 08/815,595 12 March 1997 (12.03.97) US (71) Applicants (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; West Campus, One Deaconess Road, Boston, MA 02215 (US). MEDICAL FOODS, INC. [US/US]; 238 Main Street, Suite 324, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BELL, Stacey, J. [-/US]; 56 Amherst Road, Belmont, MA 02178 (US). JONES, Robert, C. [-/US]; 109 Cross Street, Belmont, MA 02178 (US). BISTRIAN, Bruce, R. [-/US]; 189 Argilla Road, Ipswich, MA 01938 (US). FORSE, R., Armour [-/US]; 50 Fisher Avenue, Brookline, MA 02146 (US). (74) Agents: LOREN, Ralph, A. et al.; Lahive & Cockfield, L.L.P., 28 State Street, Boston, MA 02109 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: DIABETIC SUPPLEMENT BAR		
(57) Abstract A novel diabetic supplement bar which includes about 10-60 % by weight simple carbohydrate, about 1-25 % by weight protein, about 2-40 % by weight lipid and about 1-60 %, preferably about 5-35 % by weight complex carbohydrate. This formulation is particularly useful for the treatment or prevention of nighttime hypoglycemia in diabetic patients who require insulin injections.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DIABETIC SUPPLEMENT BAR.

Background of the Invention

5 The present invention relates to the control of nighttime hypoglycemia in diabetics who require insulin injections. The invention utilizes a food bar which can be administered at bedtime to control blood glucose levels.

 The results of a major study (Diabetes Control and Complication Trial)(Dawson, *Clinical Diabetes* 11:88-96, 1993), including over 1,400 diabetic patients who require regular
10 insulin administrations, have indicated that patients who maintain blood sugar levels as close as possible to normal have fewer complications resulting in neuropathy, retinopathy, and kidney disease. To accomplish this result, many patients with diabetes today follow a strict regimen, known as the "tight control" regimen. This regimen requires that the patients closely monitor their blood sugar levels (e.g., multiple tests/day), judiciously use insulin in
15 multiple doses, and strictly adhere to their diet. The unwanted side effect of tight glucose control is, however, that patients following this regimen have a three-fold increase in hypoglycemic events, more than half of which occur at nighttime.

 Hypoglycemia is a dangerous condition which develops quickly and can cause neurologic damage as well as cause a patient to go into an unconscious state, and, in rare
20 instances, a coma. Physicians want patients to be aware of the symptoms of hypoglycemia, e.g., coldness, shakiness, palpitations, and altered mentation, in order to avoid this condition. However, during sleep, the patients are not aware that they are developing hypoglycemia, so it is crucial to develop a treatment which can prevent this condition from developing at nighttime.

25 Today, patients with diabetes usually take a snack before they retire at night in attempt to avoid hypoglycemia in conjunction with a nighttime injection of insulin. The insulin is administered in order to keep the blood sugar level as close to normal as possible during sleep. Traditional snacks available today provide a carbohydrate source (usually sucrose and complex carbohydrates) which is released into the bloodstream after ingestion
30 and is taken up by cells under the influence of insulin for use as energy or storage in the form of glycogen or fat. Because of the rapid release of some of these forms of carbohydrate into the bloodstream after the ingestion, some active insulin is left over in the body during the remainder of the night. This left over insulin has no more sources of carbohydrate to interact with due to a reduction in glucose release, thus resulting in nighttime hypoglycemia.

35 Thus, a need still exists for an improved bedtime snack which can provide a continual release of glucose during the nighttime into the bloodstream to interact with insulin, thereby maintaining normal glucose levels, and can prevent nighttime hypoglycemia in diabetic patients.

- 2 -

Accordingly, an object of the invention is to provide a novel diabetic supplement bar which allows constant bloodstream glucose level during the night, thus preventing nighttime hypoglycemia in a diabetic patient.

Another object of the invention is to provide a method of preventing or treating
5 nighttime hypoglycemia in a diabetic patient by administering the diabetic supplement bar of the invention.

A further object of the invention is to control nighttime blood sugar levels of diabetic patients by administering the diabetic supplement bar of the invention near bedtime which provides phased release of glucose in the bloodstream.
10

These and other objects and features of the invention will be apparent from the following description and from the claims.

Summary of the Invention

15

The present invention features a novel diabetic supplement bar which is used for a treatment or prevention of nighttime hypoglycemia in a diabetic patient. In preferred embodiments, the diabetic supplement bar provides 100 kcal nutrition per bar and has 1 "bread exchange" and 1/2 "fat exchange" as those terms have been defined by the American
20 Diabetes Association.

The diabetic supplement bar includes about 10-60% by weight simple carbohydrate, more preferably the simple carbohydrate source provides about 4-55 kcal per 100 kcal. A simple carbohydrate source which provides about 40 kcal per 100 kcal is most preferred. The preferred simple carbohydrate is sucrose; the simple carbohydrate can also be glucose or
25 dextrose.

The diabetic supplement bar further includes about 1-25% by weight protein, preferably about 10-20 kcal per 100 kcal, most preferably about 12 kcal per 100 kcal. In preferred embodiments, only the highest biological value proteins are used, e.g., whey, lactalbumin, casein, egg white, egg solids, soy, and delactosed milk solid. Preferably, the
30 protein source may be lactose-free.

The diabetic supplement bar further includes about 2-40% by weight lipid, preferably with the lipid source providing about 10-40 kcal per 100 kcal, most preferably about 27 kcal per 100 kcal. In preferred embodiments, the lipid source comprises a medium chain triglyceride and a long chain triglyceride. The source of medium chain triglycerides is
35 preferably coconut oil, macadamia oil, palm oil, palm kernel oil, or mixtures thereof. The source of long chain triglycerides is preferably canola oil, safflower oil, sunflower oil, corn oil, olive oil, menhaden oil, peanut oil, or mixtures thereof. In further preferred embodiments, the lipid source is provided in an amount sufficient to delay gastric emptying.

- 3 -

The diabetic supplement bar further includes about 1-60%, preferably about 5-35% by weight complex carbohydrate, preferably a complex carbohydrate source which provides about 10-35 kcal per 100 kcal, most preferably about 20 kcal per 100 kcal. The preferred complex carbohydrate is uncooked cornstarch. In other preferred embodiments, the complex carbohydrates can be selected from nuts, barley, bulger, pasta, parboiled rice, dried legumes, or mixtures thereof.

In another aspect, the invention features the diabetic supplement bar which includes, in addition to the components described above (e.g., simple carbohydrates, proteins, lipids and complex carbohydrates) vitamins and minerals in accordance with, or approximately, the Recommended Dietary Allowance (RDA) (now called the Reference Daily Intake (RDI)).

The invention also features the diabetic supplement bar which includes, in addition to the components described above, inactive ingredients such as emulsifiers, artificial sweeteners and/or flavoring.

The invention also features, a method of treating or preventing nighttime hypoglycemia in a diabetic patient by administering a diabetic supplement bar to the patient, the diabetic supplement bar including about 10-60% by weight simple carbohydrate, about 1-25% by weight protein, about 2-40% by weight lipid and about 1-60%, preferably about 5-35% by weight complex carbohydrate.

In another aspect, the invention also features a method of controlling nighttime blood sugar levels in a diabetic patient by administering a diabetic supplement bar to the patient near bedtime, the diabetic supplement bar including about 10-60% by weight simple carbohydrate, about 1-25% by weight protein, about 2-40% by weight lipid and about 1-60%, preferably about 5-35% by weight complex carbohydrate.

The following description and non-limiting examples further elucidate the invention.

Detailed Description of the Invention

The diabetic supplement bar of the invention is made by blending simple carbohydrates, proteins, lipids, complex carbohydrates, and any additional additives, and homogenizing the mixture into a food bar. The food bar can contain a variable number of calories, depending upon design choice and end-user.

Although not wishing to be bound by theory, it is believed that the diabetic supplement bar of the invention prevents or treats nighttime hypoglycemia by allowing carbohydrates to be released in three phases during the night, thus providing continual flow of glucose into the blood stream to interact with insulin. The three phases are as follows: (1) a fast release of carbohydrates from simple carbohydrates, e.g., sucrose, which is readily absorbed and enters the blood stream as glucose shortly after the ingestion of the bar; (2) a more slow release phase of carbohydrates into the bloodstream from protein used by the liver

- 4 -

for gluconeogenesis. The protein gluconeogenesis allows a slow and even flow of glucose into the blood stream commencing after the glucose from the simple carbohydrate has been cleared; and (3) a slow release of simple carbohydrates from the hydrolysis of complex carbohydrates, e.g., corn starch. Complex carbohydrates are hydrolyzed by intestinal
5 enzymes more slowly than other forms of carbohydrates, resulting in delayed intestinal absorption long after the bar is ingested. Lipids in the form of medium and long chain triglycerides are added to the bar both as an energy source and to delay overall gastric emptying, so that all of the aforementioned processes occur more slowly.

In practice of the present invention, sucrose is the preferred source of simple
10 carbohydrates. While glucose and dextrose may also be used, fructose should be avoided as fructose has undesirable effects on the metabolism which include lactic acid production and impairment of gluconeogenesis by the liver.

The lipid source of the diabetic supplement bar of the invention may comprise a mixture of medium chain triglycerides (MCTs) and long chain triglycerides (LCTs).
15 Examples of suitable MCT sources include coconut oil, macadamia oil, palm oil, palm kernel oil, or mixtures thereof. Examples of suitable LCT sources canola oil, safflower oil, sunflower oil, corn oil, olive oil, menhaden oil, evening primrose oil, peanut oil, or mixtures thereof. The lipid source should be added to the diabetic supplement bar in the amount sufficient to delay gastric emptying. Additional sources of MCTs and LCTs are discussed in
20 US Patent No. 4,703,062, which is herein incorporated by reference.

The protein may be any suitable protein utilized in a nutritional formula such as soy protein, casein protein, whey protein, animal and vegetable protein, and mixtures thereof. For greatest use, the protein source should be lactose-free so it can be used for lactose
25 intolerant patients. When choosing a protein source, the biological value of the protein should be considered first, with the highest biological values being found in casein, whey, lactalbumin, egg albumin, and whole egg proteins. Next, the cost should be considered, the lowest cost with the best biological value being the best combination.

Uncooked cornstarch is the preferred source of complex carbohydrate because it carbohydrate content is relatively uniform, its rate of metabolism is both known and
30 consistent, and it can be readily formulated into an easy to administer food bar. Additional sources of complex carbohydrates which can be used in the practice of the present invention include nuts, barley, bulger, pasta, parboiled rice, dried legumes, or mixtures thereof. Uncooked cornstarch is commercially available from a number of suppliers, e.g., it is available under the trade name "mellojel" from the National Starch and Chemical company.
35 In addition, in children under the age of two years, it is also preferred that the complex carbohydrate be administered together with the enzyme pancrease in an amount useful to promote digestion of complex carbohydrate. The pancrease is given adjunctively, usually in a dosage of about 1/4 teaspoon of pancrease per 5 grams of complex carbohydrate.

- 5 -

Emulsifiers may be added for stability purposes to the diabetic supplement bar of the invention, e.g., emulsifiers such as lecithin.

Flavoring may also be added to the diabetic supplement bar of the invention to make it more palatable. Flavoring can be in a form of flavored extracts, volatile oils, chocolate
5 flavoring, peanut butter flavoring, cookie crumbs, vanilla or any commercially available
flavoring. For example, if flavoring which contains fat is used (e.g., chocolate flavoring
contains butter fat), the fat concentration of the diabetic supplement bar of the invention
should be adjusted accordingly so that the final fat concentration remains the same, i.e., the
final fat concentration does not exceed 40% by weight fat.

10 Preservatives may also be added to the diabetic supplement bar of the invention to
extend its shelf time. Preferably, preservatives such as potassium sorbate, sodium sorbate,
potassium benzoate, sodium benzoate or calcium disodium EDTA are used.

In addition to the carbohydrates, artificial sweeteners, e.g., saccharides, cyclamates, or
aspartame, may also be added to the diabetic supplement bar of the invention. Sorbitol
15 should be avoided as a sweetener because sorbitol is not metabolized well by diabetic patients
and in large quantities can cause diarrhea.

To prevent nighttime hypoglycemia during overnight sleep periods, the diabetic
supplement bar of the invention is administered to the patient at bedtime. For example, the
bar can be designed to provide 100 kcal of nutrition in the form of 1 bread exchange and 1/2
20 fat exchange. However, bars containing other exchange values depending upon the caloric
value of the bar are embraced by this invention. Such exchange values are readily ascertained
by the American Dietetic Association and the American Diabetes Association. The bar of the
invention provides a sufficient amount of circulating carbohydrates so that the patient passes
the nocturnal sleep time without need for glucose intervention and awakens after about six to
25 eight hours of sleep with a glucose level 60 mg/deciliter or greater. In addition, the diabetic
supplement bar of the invention is dividable into smaller defined portions, e.g., four portions,
so that each portion provides a controlled amount of calories. Any other possible partitions
of the bar, e.g., where each portion may provide 10, 20, 25 or 50 kcal of nutrition, are also
intended to be encompassed by this invention. Accordingly, the amount of the bar needed at
30 bed time can be controlled depending on what the patient has eaten that day, e.g., the amount
of food exchanges ingested before bedtime.

Certain terms used herein are described below for clarity.

As used herein the term "diabetic patient" refers to any patient who requires insulin
injections to maintain blood glucose level as close as possible to a normal range, e.g., 80-120
35 mg/deciliter. For example, the patient suffers from diabetes, e.g., type I diabetes or type II
diabetes and requires regular insulin administrations.

As used herein the term "hypoglycemia" refers to a clinical condition that results from
low blood glucose levels, e.g., blood glucose levels of less than or equal to 3.0 mmol/liter or

- 6 -

60 mg/deciliter of whole blood. Symptoms of hypoglycemia fall into two main categories. Rapid epinephrine release can cause sweating, tremor, tachycardia, anxiety, and hunger. Central nervous system symptoms can include dizziness, headache, clouding of vision, blunted mental acuity, confusion, abnormal behavior, convulsions, and loss of consciousness.

5

Example 1

This Example describes a diabetic supplement bar of the invention. The basic
10 ingredients of the diabetic supplement bar (total weight 25 g) are set forth in Table 1.

TABLE 1

Ingredient	Amount per 100 kcal (grams)	Total caloric contribution (kcal)	% of total caloric contribution
simple carbohydrate (sucrose)	10	40	40
protein (whey, casein or soy)	3	12	12
medium-chain triglycerides (coconut oil, palm oil and/or palm kernel oil)	1	8.3	8.3
long-chain triglycerides (canola oil)	2.1	18.9	18.9
complex carbohydrate (uncooked corn starch)	5	20	20

15

The possible additives to the diabetic supplement bar of the invention are set forth in Table 2.

Table 2
ADDITIVES

Ingredient	Amount per bar (total weight 25 g)
elemental Ca ⁺⁺	250 mg
vitamin C	30 mg
lecithin	0.5-2%
cookie crumb or vanilla	0.5-2%
potassium sorbate	500 mg

- 7 -

1. Emulsifier: lecithin

2. Flavoring: flavoring can be in the form of a flavored extract, e.g., pure anise extract (73% ethanol), imitation banana extract (40% ethanol), imitation cherry extract (24% ethanol), chocolate extract (23% ethanol), pure lemon extract (84% ethanol), pure orange extract (80% ethanol), pure peppermint extract (89% ethanol), imitation pineapple extract (42% ethanol), imitation rum extract (35% ethanol), imitation strawberry extract (30% ethanol), or pure vanilla extract (35% ethanol); or volatile oils, e.g., balm oil, bay oil, bergamot oil, cedarwood oil, cherry oil, cinnamon oil, clove oil, origanum oil, or peppermint oil; peanut butter, chocolate flavoring, vanilla, cookie crumb, butterscotch or toffee in propylene glycol.

10

Example 2

This example outlines one possible processing procedure for formulating the diabetic supplement bar of the invention.

15

This procedure can be carried out manually by a pharmacist or other trained personnel (kitchen help). The method of making the diabetic supplement bar of the invention can best be carried out by blending all of the ingredients in a blender and molding them into a bar. The total weight of the bar should not exceed 25 g including all the additives.

20

The foregoing examples are purely illustrative and are not intended to be the limitation of the invention. Those skilled in the art can determine other modifications on the diabetic supplement bar used herein. Such modifications are included within the following claims.

25

What is claimed is:

CLAIMS

1. A diabetic supplement bar comprising:
about 10-60% by weight simple carbohydrate;
5 about 1-25% by weight protein;
about 2-40% by weight lipid; and
about 1-60% by weight complex carbohydrate,
wherein the diabetic supplement bar is used for a prevention of nighttime
hypoglycemia in a diabetic patient.
10
2. The diabetic supplement bar of claim 1, wherein the simple carbohydrate source
provides about 4-55 kcal per 100 kcal.
3. The diabetic supplement bar of claim 1, wherein the simple carbohydrate is selected
15 from the group consisting of sucrose, glucose, and dextrose.
4. The diabetic supplement bar of claim 1, wherein the protein source provides about 10-
20 kcal per 100 kcal.
- 20 5. The diabetic supplement bar of claim 1, wherein the protein is selected from the group
consisting of whey, lactalbumin, casein, egg white, egg solids, soy, and delactosed milk solid.
6. The diabetic supplement bar of claim 1, wherein the lipid source provides about 10-40
kcal per 100 kcal.
25
7. The diabetic supplement bar of claim 6, wherein the lipid source comprises a medium
chain triglyceride and a long chain triglyceride.
8. The diabetic supplement bar of claim 7, wherein the source of a medium chain
30 triglyceride is selected from the group consisting of coconut oil, macadamia oil, palm oil,
palm kernel oil, and mixtures thereof.
9. The diabetic supplement bar of claim 7, wherein the long chain triglyceride is selected
from the group consisting of canola oil, safflower oil, sunflower oil, corn oil, olive oil,
35 menhaden oil, peanut oil, and mixtures thereof.
10. The diabetic supplement bar of claim 1, wherein the complex carbohydrate source
provides about 10-35 kcal per 100 kcal.

- 9 -

11. The diabetic supplement bar of claim 1, wherein the complex carbohydrate is selected from the group consisting of uncooked corn starch, nuts, barley, bulger, pasta, parboiled rice, dried legumes, and mixtures thereof.
- 5 12. The diabetic supplement bar of claim 1, wherein the bar further comprises sources of vitamins and minerals.
- 10 13. The diabetic supplement bar of claim 1, wherein the bar further comprises an emulsifier.
14. The diabetic supplement bar of claim 1, wherein the bar further comprises a flavoring.
- 15 15. The diabetic supplement bar of claim 1, wherein the lipid source is in an amount sufficient to delay gastric emptying.
- 20 16. A method of preventing nighttime hypoglycemia in a diabetic patient comprising administering a diabetic supplement bar to the patient, the diabetic supplement bar comprising about 10-60% by weight simple carbohydrate, about 1-25% by weight protein, about 2-40% by weight lipid and about 1-60% by weight complex carbohydrate.
17. The method of claim 16, wherein the diabetic patient requires insulin injections.
- 25 18. The method of claim 16, wherein the simple carbohydrate source provides about 4-55 kcal per 100 kcal.
19. The method of claim 16, wherein the simple carbohydrate is selected from the group consisting of sucrose, glucose, and dextrose.
- 30 20. The method of claim 16, wherein the protein source provides about 10-20 kcal per 100 kcal.
21. The method of claim 16, wherein the protein is selected from the group consisting of whey, lactalbumin, casein, egg white, egg solids, soy, and delactosed milk solid.
- 35 22. The method of claim 16, wherein the lipid source provides about 10-40 kcal per 100 kcal.

- 10 -

23. The method of claim 22, wherein the lipid source comprises a medium chain triglyceride and a long chain triglyceride.

24. The method of claim 23, wherein the source of a medium chain triglyceride is
5 selected from the group consisting of coconut oil, macadamia oil, palm oil, palm kernel oil, and mixtures thereof.

25. The method of claim 23, wherein the long chain triglyceride is selected from the
10 group consisting of canola oil, safflower oil, sunflower oil, corn oil, olive oil, menhaden oil, peanut oil and mixtures thereof.

26. The method of claim 16, wherein the complex carbohydrate source provides about 10-35 kcal per 100 kcal.

15 27. The method of claim 16, wherein the complex carbohydrate is selected from the group consisting of uncooked corn starch, nuts, barley, bulger, pasta, parboiled rice, dried legumes, and mixtures thereof.

20 28. The method of claim 16, wherein the bar further comprises sources of vitamins and minerals.

29. The method of claim 16, wherein the bar further comprises an emulsifier.

25 30. The method of claim 16, wherein the bar further comprises a flavoring.

31. The method of claim 16, wherein the lipid source is in an amount sufficient to delay gastric emptying in the patient.

30 32. A method of controlling nighttime blood sugar levels in a diabetic patient comprising administering a diabetic supplement bar to the patient near bedtime, the diabetic supplement bar comprising about 10-60% by weight simple carbohydrate, about 1-25% by weight protein, about 2-40% by weight lipid and about 1-60% by weight complex carbohydrate.

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/US 97/05316

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A23L1/29 A23L1/09 A23L1/30 A23L1/305 A61K31/70
A61K31/715

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 127 287 A (NABISCO) 5 December 1984	1,3,16, 19
A	see page 11, line 22 - page 12, line 2; claims 1,3-9,14,15; examples 1,2	2,4-15, 17,20-32
A	US 5 169 662 A (A.SPICER) 8 December 1992 see column 1, line 10-14 see column 5, line 6-8; claims	1-32
A	US 5 360 614 A (J.G.FOX ET AL.) 1 November 1994 see column 7, line 58 - column 8, line 31; claims; example 10	1-32
A	US 4 703 062 A (G.L.BLACKBURN ET AL) 27 October 1987 cited in the application see the whole document	1,7-9, 23-25
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 August 1997

Date of mailing of the international search report

04.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Van Moer, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/05316

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 96 31129 A (CHILDREN'S HOSPITAL OF LOS ANGELES) 10 October 1996 see page 5, line 3; claims 1-5,7-13 ---	1-32
E	EP 0 768 043 A (BRISTOL-MYERS SQUIBB) 16 April 1997 see page 1, line 1-5 see page 3, line 42 - page 4, line 5 see page 4, line 48 see page 5, line 4-8 see claims 1-13; examples 1,3,6 ---	1-32
E	US 5 612 074 A (R.L.LEACH) 18 March 1997 see claims -----	1-32

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/05316

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16-32
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 16 to 32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/05316

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 127287 A	05-12-84	US 4496606 A CA 1204619 A	29-01-85 20-05-86
US 5169662 A	08-12-92	NONE	
US 5360614 A	01-11-94	AU 6712894 A BR 9406053 A CA 2161518 A EP 0713366 A JP 8509734 T WO 9424884 A US 5536156 A US 5545410 A	21-11-94 26-12-95 10-11-94 29-05-96 15-10-96 10-11-94 16-07-96 13-08-96
US 4703062 A	27-10-87	AU 3748285 A CA 1242974 A EP 0168425 A JP 61501558 T WO 8503002 A	30-07-85 11-10-88 22-01-86 31-07-86 18-07-85
WO 9631129 A	10-10-96	US 5605893 A AU 3372895 A CA 2191714 A EP 0765126 A FI 964884 A ZA 9507800 A	25-02-97 23-10-96 10-10-96 02-04-97 06-02-97 06-05-96
EP 768043 A	16-04-97	AU 6818896 A CA 2187394 A	24-04-97 17-04-97
US 5612074 A	18-03-97	NONE	



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23L 1/29, 1/09, 1/30, 1/305, A61K 31/70, 31/715	A1	(11) International Publication Number: WO 97/38593 (43) International Publication Date: 23 October 1997 (23.10.97)
(21) International Application Number: PCT/US97/05316 (22) International Filing Date: 28 March 1997 (28.03.97) (30) Priority Data: 08/631,584 12 April 1996 (12.04.96) US 08/815,595 12 March 1997 (12.03.97) US (71) Applicants (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; West Campus, One Deaconess Road, Boston, MA 02215 (US). MEDICAL FOODS, INC. [US/US]; 238 Main Street, Suite 324, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BELL, Stacey, J. [US/US]; 56 Amherst Road, Belmont, MA 02178 (US). JONES, Robert, C. [US/US]; 109 Cross Street, Belmont, MA 02178 (US). BISTRIAN, Bruce, R. [US/US]; 189 Argilla Road, Ipswich, MA 01938 (US). FORSE, R., Armour [CA/US]; 50 Fisher Avenue, Brookline, MA 02146 (US). (74) Agents: LOREN, Ralph, A. et al.; Lahive & Cockfield, L.L.P., 28 State Street, Boston, MA 02109 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: DIABETIC SUPPLEMENT BAR (57) Abstract A novel diabetic supplement bar which includes about 10-60 % by weight simple carbohydrate, about 1-25 % by weight protein, about 2-40 % by weight lipid and about 1-60 %, preferably about 5-35 % by weight complex carbohydrate. This formulation is particularly useful for the treatment or prevention of nighttime hypoglycemia in diabetic patients who require insulin injections.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						